Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Non Operating Income (2016 - 2025)

Regenxbio has reported Non Operating Income over the past 12 years, most recently at -$9.5 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 5326.92% year-over-year to -$9.5 million; the TTM value through Dec 2025 reached -$32.7 million, down 623.38%, while the annual FY2025 figure was -$32.7 million, 623.38% down from the prior year.
  • Non Operating Income for Q4 2025 was -$9.5 million at Regenxbio, roughly flat from -$9.5 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $3.1 million in Q3 2023 and troughed at -$9.5 million in Q3 2025.
  • A 5-year average of -$2.9 million and a median of -$3.3 million in 2022 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: soared 202.7% in 2024 and later crashed 5326.92% in 2025.
  • Year by year, Non Operating Income stood at -$6.2 million in 2021, then skyrocketed by 64.23% to -$2.2 million in 2022, then soared by 139.06% to $862000.0 in 2023, then crashed by 78.89% to $182000.0 in 2024, then crashed by 5326.92% to -$9.5 million in 2025.
  • Business Quant data shows Non Operating Income for RGNX at -$9.5 million in Q4 2025, -$9.5 million in Q3 2025, and -$7.6 million in Q2 2025.